- Home
- GNLX vs RILYP Comparison
GNLX vs RILYP Comparison
Compare GNLX & RILYP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.44
Company Overview
Basic Information| Metric | GNLX | RILYP |
|---|---|---|
| Founded | 2001 | 1973 |
| Country | United States | United States |
| Employees | N/A | 2056 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | N/A |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | GNLX | RILYP |
|---|---|---|
| Price | $2.44 | $10.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $19.80 | N/A |
| AVG Volume (30 Days) | ★ 129.7K | 18.3K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.03% |
| EPS Growth | ★ 9.47 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $854,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.99 | $1.75 |
| 52 Week High | $8.54 | $14.50 |
Technical Indicators
Market Signals| Indicator | GNLX | RILYP |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 59.77 |
| Support Level | $2.35 | $8.56 |
| Resistance Level | $3.00 | $11.47 |
| Average True Range (ATR) | 0.15 | 0.91 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 21.51 | 75.32 |
Price Performance
Historical Comparison GNLX
RILYP
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.